Trisk Bio and NanoMosaic have announced a strategic partnership to integrate NanoMosaic’s Tessie analytics platform into Trisk Bio’s adeno-associated virus (AAV) development and manufacturing workflows. The collaboration will support process development, quality control, and release testing services across Trisk’s gene therapy manufacturing operations. Trisk adopted the Tessie platform ahead of its broader market recognition and prior to the FDA CBER granting the technology an Advanced Manufacturing Technology (AMT) designation in January 2026 the first such recognition in AAV analytics. The companies believe the partnership will help improve the accuracy of measuring critical quality attributes in gene therapy manufacturing, an area where traditional analytics can produce inconsistent results.
Also Read: Clinical AI Launches MAIA™ Prescreening on Google Cloud Marketplace to Accelerate Clinical Trials
“We are pleased to see the FDA validate the advantages that have been clear to us from our first engagements with NanoMosaic,” said Gaurav Venkataraman, Trisk Bio CEO. “Trisk is oriented around helping our clients become successful by providing high-quality material and de-risking manufacturing from the start. Legacy AAV analytics can misread critical quality attributes by orders of magnitude. It’s critical that our clients’ programmes rest on technology yielding the most accurate possible measurements.”